MedTrace Logo

Mesenchymal Stem Cells Transplantation for Liver Cirrhosis Due to HCV Hepatitis

NCT02705742 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2016-06-07

No results posted yet for this study

Summary

In this study, investigators aimed to transplant autologous, adipose tissue derived mesenchymal stem cells to the patients with liver cirrhosis due to HCV. We also aimed to assess liver tissue regeneration, downgrade of clinical findings and antiviral efficacy. Finally investigators aimed to establish an alternative treatment modality to liver transplantation.

Conditions

Interventions

BIOLOGICAL

Mesenchymal Stem Cells

1.000.000 (one million) cells/kg, IV of dose in the Peripheral vein and 3.000.000 (three million) cells/kg of dose into the right hepatic artery)

Sponsors & Collaborators

  • Saglik Bilimleri Universitesi Gulhane Tip Fakultesi

    lead OTHER

Principal Investigators

  • Murat Kantarcioglu, M.D. · Gulhane Military Medical Academy, Department of Gastroenterology

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-31
Primary Completion
2017-07-31
Completion
2017-12-31

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02705742 on ClinicalTrials.gov